Dear Editor: The recent report on serum anti-Müllerian hormone (AMH) levels and phenotypes of polycystic ovary syndrome is very interesting [1]. Hwang et al. [1] concluded that “high serum AMH levels cannot predict the phenotype of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients in the non-obese group”. Notably, the results from this work are totally different from ...

During male sexual differentiation, the transforming growth factor-β (TGF-β) signaling molecule anti-Müllerian hormone (AMH; also known as Müllerian inhibiting substance, MIS) is secreted by the fetal testes and induces regression of the Müllerian ducts, the primordia of the female reproductive tract organs. Currently, the molecular identity of downstream events regulated by the AMH signaling p...

Progressive addition of hydroxypropylated amylose (AmH), from 0.05 wt% to 4.5 wt%, to single-walled carbon nanotubes (SWNTs) in aqueous surfactant suspensions quenches the intrinsic near Infra-Red fluorescence of semiconducting SWNTs while dispersions obtained with a same amount of polyvinylpyrrolidone (PVP) remain luminescent. Near Infra-Red emission spectroscopy (fluorescence and Raman scatte...

OBJECTIVE [corrected] To improve the biologic understanding of the Polycystic Ovarian Syndrome (PCOS) condition by examining the circadian variation and relationship between Anti Müllerian Hormone (AMH), gonadotropins and ovarian steroids in PCOS patients compared to normally ovulating and menstruating women. By comparing the pattern of co-variation between AMH and Luteinizing Hormone, two comp...

BACKGROUND Stratified (individualized) medicine has been recognized as a key priority for policy makers and healthcare providers. The main principle of individualized care depends on utilizing patients' characteristics and biomarkers to predict prognosis, tailor intended treatment and predict treatment outcomes. In reproductive medicine a wide variety of biomarkers have been proposed as predict...

BACKGROUND Anti-Müllerian hormone (AMH) is secreted by granulosa cells of ovarian early developing follicles and its serum levels have been shown to correlate with small antral follicle number. Since the pronounced androgen secretion from follicles/stroma in women with polycystic ovary syndrome (PCOS) remains until late reproductive age, and since AMH reflects the number of antral follicles, it...

CONTEXT Polycystic ovary syndrome (PCOS) is an anovulatory disorder characterized by excess androgen production and increased LH secretion. Serum anti-Mullerian hormone (AMH) is also elevated in this disorder. Women with PCOS exhibit a positive correlation between AMH and LH levels and recent in vitro data demonstrate that LH can directly stimulate AMH production by granulosa cells from women w...

Background: Reproductive age may be a risk factor for vascular disease. Anti-Müllerian hormone (AMH) is produced by viable ovarian follicles and reflects reproductive age. We examined whether AMH concentrations were associated with markers of subclinical cardiovascular disease (CVD) and kidney disease among women with type 1 diabetes. Methods: We performed a cross-sectional analysis of the Epid...

Background: Measurement of anti-Müllerian hormone (AMH) is a valuable clinical tool for evaluating ovarian function. The present study aims to evaluate the reliability of AMH measurements obtained from samples kept for long-term storage with or without intermittent thawing. Methods and findings: Serum samples from 35 young female cancer patients were prospectively collected and stored at -80°C ...

OBJECTIVE This retrospective study determined for the first time the role of baseline antral follicle count (AFC) and serum anti-Mullerian hormone (AMH) level in the first in-vitro fertilisation (IVF) cycle in predicting cumulative live birth from one stimulation cycle. METHODS We studied 1,156 women (median age 35 years) undergoing the first IVF cycle. Baseline AFC and AMH level on the day b...